石四药集团(02005)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02005 石四药集团

已收盘 09-24 16:08:31

2.795

+0.000

0.00%

最高2.810	最低2.770	成交量273.60万
今开2.800	昨收2.795	日振幅1.43%
总市值80.66亿	流通市值80.66亿	总股本28.86亿
成交额763.63万	换手率0.09%	流通股本28.86亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02005","market":"HK","secType":"STK","nameCN":"石四药集团","latestPrice":2.795,"timestamp":1790237311003,"preClose":2.795,"halted":0,"volume":2736000,"delay":0,"changeRate":0,"floatShares":2886000000,"shares":2886000000,"eps":0.1605,"marketStatus":"已收盘","change":0,"latestTime":"09-24 16:08:31","open":2.8,"high":2.81,"low":2.77,"amount":7636340,"amplitude":0.014311,"askPrice":2.795,"askSize":26000,"bidPrice":2.775,"bidSize":64000,"shortable":3,"etf":0,"ttmEps":0.174609,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790299800000},"marketStatusCode":5,"adr":0,"listingDate":1135008000000,"exchange":"SEHK","adjPreClose":2.795,"dividendRate":0.030376,"openAndCloseTimeList":[[1790213400000,1790222400000],[1790226000000,1790236800000]],"volumeRatio":0.717721,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02005","defaultTab":"news","newsList":[{"id":"1180553474","title":"石四药集团：曲继广增持，好仓比例升至43.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=1180553474","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180553474?lang=zh_cn&edition=full","pubTime":"2026-09-23 17:50","pubTimestamp":1790157042,"startTime":"0","endTime":"0","summary":"曲继广于2026年9月23日通过其控制的公司在联交所场内以每股均价2.797港元买入石四药集团125.00万股，涉资约349.62万港元，属场内主动交易，即在二级市场直接买卖股份。曲继广此次增持前持有石四药集团好仓12.78亿股，占比43.31%；增持后持股量为12.79亿股，好仓比例升至43.35%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118164241","title":"石四药集团：China Pharmaceutical Company Limited增持，好仓比例升至31.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=1118164241","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118164241?lang=zh_cn&edition=full","pubTime":"2026-09-23 17:12","pubTimestamp":1790154734,"startTime":"0","endTime":"0","summary":"China Pharmaceutical Company Limited于2026年9月23日以每股均价2.7970港元场外买入125.00万股石四药集团股份，涉资约349.62万港元，属场外交易（未经联交所公开市场撮合，不属二级市场直接买卖）。该笔交易为自愿披露。China Pharmaceutical Company Limited此次增持前持有石四药集团好仓9.21亿股，占比31.22%；增持后持股量为9.23亿股，好仓比例升至31.26%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176902139","title":"石四药集团：曲继广增持，好仓比例升至43.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=1176902139","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176902139?lang=zh_cn&edition=full","pubTime":"2026-09-22 17:42","pubTimestamp":1790070137,"startTime":"0","endTime":"0","summary":"曲继广于2026年9月22日在联交所场内以每股均价2.7624港元买入石四药集团股份100.00万股，涉资约276.24万港元，属场内主动交易，即在二级市场直接买卖股份。曲继广此次增持前持有石四药集团好仓12.77亿股，占比43.27%；增持后持股量为12.78亿股，好仓比例升至43.31%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f7700173111443e192ac74957e46cb69","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162389697","title":"石四药集团回购100万股股份，总额约276.24万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1162389697","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162389697?lang=zh_cn&edition=full","pubTime":"2026-09-22 16:56","pubTimestamp":1790067387,"startTime":"0","endTime":"0","summary":"2026年9月22日，石四药集团有限公司发布翌日披露报表称，公司于当日于香港联交所场内回购合计100万股股份，约占本次回购前公司已发行股本的0.035%。每股回购价格介乎港币2.745元至2.77元，总计耗资约2,762,370港元，折合约276.24万港元。本次回购完成后，公司已发行股份由原先的2,886,593,385股减少至2,885,593,385股，同时库藏股由64,520,000股增加至65,520,000股。公司在公告中确认已遵守香港联交所证券上市规则及相关法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石四药集团回购100万股股份，总额约276.24万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669117256","title":"石四药集团(02005)9月22日斥资276.24万港元回购100万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669117256","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669117256?lang=zh_cn&edition=full","pubTime":"2026-09-22 16:50","pubTimestamp":1790067032,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，该公司于2026年9月22日斥资276.24万港元回购100万股股份，每股回购价格为2.745-2.77港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1499298.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02005","BK1191","LU2460026573.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164573904","title":"石四药集团：曲继广增持，好仓比例升至43.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=1164573904","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164573904?lang=zh_cn&edition=full","pubTime":"2026-09-21 17:51","pubTimestamp":1789984268,"startTime":"0","endTime":"0","summary":"曲继广于2026年9月21日在联交所场内以每股均价2.7495港元买入石四药集团股份80.00万股，涉资约219.96万港元，属场内主动交易，即在二级市场直接买卖股份。曲继广此次增持前持有石四药集团好仓12.76亿股，占比43.25%；增持后持股量为12.77亿股，好仓比例升至43.27%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124129307","title":"石四药集团回购80万股股份，斥资约220万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1124129307","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124129307?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:39","pubTimestamp":1789979982,"startTime":"0","endTime":"0","summary":"石四药集团于2026年9月21日公告称，公司于当日在香港联交所场内回购股份80万股，约占回购前公司已发行股本的0.028%。本次回购价格区间为每股2.735港元至2.755港元，合计耗资约219.96万港元。本次回购完成后，公司已发行股份总数仍为2,951,113,385股，其中2,886,593,385股为已发行且未被持作库藏的股份，库藏股数量增至64,520,000股。公司强调，本次操作符合香港联合交易所有限公司证券上市规则及适用法律法规的相关规定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石四药集团回购80万股股份，斥资约220万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669156029","title":"石四药集团(02005)9月21日斥资219.96万港元回购80万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2669156029","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669156029?lang=zh_cn&edition=full","pubTime":"2026-09-21 16:33","pubTimestamp":1789979637,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，于2026年9月21日，该公司斥资219.96万港元回购80万股股份，每股回购价2.735-2.755港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498705.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2460026573.USD","BK1191","02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144774423","title":"石四药集团：曲继广增持，好仓比例升至43.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=1144774423","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144774423?lang=zh_cn&edition=full","pubTime":"2026-09-17 17:42","pubTimestamp":1789638148,"startTime":"0","endTime":"0","summary":"曲继广于2026年9月17日在联交所场内以每股均价2.7675港元买入石四药集团140.00万股股份，涉资约387.45万港元。该买入通过其控制的法团进行，属场内主动交易，即在二级市场直接买卖股份。曲继广此次增持前持有石四药集团好仓12.74亿股，占比43.16%；增持后持股量为12.75亿股，好仓比例升至43.21%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108171264","title":"石四药集团：China Pharmaceutical Company Limited增持，好仓比例升至31.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=1108171264","media":"港股披露","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108171264?lang=zh_cn&edition=full","pubTime":"2026-09-17 17:32","pubTimestamp":1789637525,"startTime":"0","endTime":"0","summary":"China Pharmaceutical Company Limited于2026年9月17日以每股均价2.7675港元场外增持石四药集团（02005）140.00万股，涉资约387.45万港元。该笔为场外交易，未经联交所公开市场撮合，不属二级市场直接买卖。China Pharmaceutical Company Limited此次增持前持有石四药集团好仓9.19亿股，占比31.13%；增持后持股量为9.20亿股，好仓比例升至31.18%。原文链接：Hong Kong Exchanges and Clearing Limited","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194179512","title":"石四药集团(02005)甲磺酸齐拉西酮原料药获国家药监局登记批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1194179512","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194179512?lang=zh_cn&edition=full","pubTime":"2026-09-16 17:18","pubTimestamp":1789550338,"startTime":"0","endTime":"0","summary":"2026年9月16日，石四药集团有限公司(02005)发布自愿公告称，其甲磺酸齐拉西酮已获中国国家药品监督管理局批准登记为在上市制剂中使用的原料药。甲磺酸齐拉西酮主要用于治疗精神分裂症患者的急性激越症状。\n公告指出，此次获批进一步完善公司二代抗精神病高活性原料药(HPAPI)产品矩阵。目前，石四药集团已建成涵盖布南色林、鲁拉西酮、盐酸齐拉西酮以及甲磺酸齐拉西酮的国内领先二代抗精神病HPAPI平台，为国内制剂企业提供高品质原料药供应链支持。\n公司表示，本次公告旨在让股东及潜在投资者了解最新业务发展情况。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667194609","title":"石四药集团(02005)：甲磺酸齐拉西酮获批成为在上市制剂使用的原料药","url":"https://stock-news.laohu8.com/highlight/detail?id=2667194609","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667194609?lang=zh_cn&edition=full","pubTime":"2026-09-16 17:02","pubTimestamp":1789549365,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，集团的甲磺酸齐拉西酮已获中国国家药品监督管理局批准登记成为在上市制剂使用的原料药。甲磺酸齐拉西酮主要用于治疗精神分裂症患者的急性激越症状。此次获批进一步完善集团二代抗精神病高活性原料药(HPAPI)产品矩阵。目前集团已建成国内领先的二代抗精神病 HPAPI 平台，覆盖布南色林、鲁拉西酮、盐酸齐拉西酮及此次获批的甲磺酸齐拉西酮，持续为国内制剂企业提供高品质原料药供应链支撑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496832.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2460026573.USD","02005","IPOS","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667609691","title":"石四药集团(02005)9月16日斥资230.4万港元回购85万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667609691","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667609691?lang=zh_cn&edition=full","pubTime":"2026-09-16 16:56","pubTimestamp":1789548967,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，该公司于2026年9月16日斥资230.4万港元回购85万股股份，每股回购价格为2.68-2.725港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1496820.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2460026573.USD","BK1191","02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194010394","title":"石四药集团回购85万股，涉资约230.40万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1194010394","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194010394?lang=zh_cn&edition=full","pubTime":"2026-09-16 16:55","pubTimestamp":1789548947,"startTime":"0","endTime":"0","summary":"石四药集团有限公司于2026年9月16日发布公告，披露于当日在香港联交所场内回购85万股普通股，约占回购前已发行股本的0.029%。此次回购每股价格介乎2.68港元至2.725港元，总金额约230.40万港元。回购完成后，石四药集团的已发行股本降至28.87393385亿股，同时库藏股数量增加至6372万股。公告显示，购回授权于2026年5月15日获得通过，目前公司可根据该授权继续回购股份的总数为289924338股，截至本次回购累计已回购11850000股，占授权通过日已发行股本的0.409%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石四药集团回购85万股，涉资约230.40万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164128528","title":"石四药集团2026年上半年营收23.61亿元，经调整净利润3.20亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1164128528","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164128528?lang=zh_cn&edition=full","pubTime":"2026-09-14 17:02","pubTimestamp":1789376543,"startTime":"0","endTime":"0","summary":"2026年上半年，石四药集团实现营收约23.61亿元，同比增长9.9%。整体毛利率为41.2%，较去年同期的41.5%下降0.3个百分点。经营利润率则由上年同期的18.9%提升至20.1%。期内经营活动所产生的现金流约为5.13亿元，同比增长约213%。上半年，石四药集团静脉输液及其他业务实现销售收入约22.42亿元，同比上涨约9.6%，在营收中占比继续保持高位。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"石四药集团2026年上半年营收23.61亿元，经调整净利润3.20亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164998648","title":"石四药集团9月14日回购320万股股份，涉资约837.07万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1164998648","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164998648?lang=zh_cn&edition=full","pubTime":"2026-09-14 16:36","pubTimestamp":1789374969,"startTime":"0","endTime":"0","summary":"石四药集团有限公司于2026年9月14日公告称，公司当日在香港联交所场内回购普通股3,200,000股，占该事件前已发行股本的约0.111%。本次回购的最高价为每股2.66港元，最低价为2.585港元，合计支付价格总额8,370,700港元。本次回购股份将全部作为库藏股持有。回购完成后，公司已发行股本为2,888,243,385股，库藏股数量增至62,870,000股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"石四药集团9月14日回购320万股股份，涉资约837.07万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667659946","title":"石四药集团(02005)9月14日斥资837.07万港元回购320万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2667659946","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667659946?lang=zh_cn&edition=full","pubTime":"2026-09-14 16:33","pubTimestamp":1789374785,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，于2026年9月14日，该公司斥资837.07万港元回购320万股股份，每股回购价2.585-2.66港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495612.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02005","BK1191","LU2460026573.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666552540","title":"石四药集团(02005.HK)已取得中国国家药品监督管理局有关来特莫韦注射液(12ml:240mg)的药品生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2666552540","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666552540?lang=zh_cn&edition=full","pubTime":"2026-09-10 12:03","pubTimestamp":1789013027,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2460026573.USD","BK1191","02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666555243","title":"石四药集团：来特莫韦注射液获药品生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2666555243","media":"南方财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666555243?lang=zh_cn&edition=full","pubTime":"2026-09-10 12:03","pubTimestamp":1789013000,"startTime":"0","endTime":"0","summary":"南财智讯9月10日电，石四药集团（02005.HK）发布自愿公告，公司已取得中国国家药品监督管理局关于来特莫韦注射液（12ml:240mg）的药品生产注册批件，该产品属于化学药品第4类，视同通过一致性评价。来特莫韦注射液主要用于接受异基因造血干细胞移植的巨细胞病毒（CMV）血清学阳性的成人受者，预防巨细胞病毒感染和巨细胞病毒病，需联合基础输液使用，应用于造血干细胞移植围手术期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609103870408176.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609103870408176.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","LU2460026573.USD","02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666587479","title":"China Pharmaceutical Company Limited增持石四药集团(02005.HK)88万股 每股作价约2.73港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2666587479","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666587479?lang=zh_cn&edition=full","pubTime":"2026-09-09 19:02","pubTimestamp":1788951757,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2460026573.USD","BK1191","02005"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ssygroup.com.hk","stockEarnings":[{"period":"1week","weight":0.0257},{"period":"1month","weight":0.1573},{"period":"3month","weight":0.3209},{"period":"6month","weight":0.2042},{"period":"1year","weight":0.0036},{"period":"ytd","weight":0.0212}],"compareEarnings":[{"period":"1week","weight":0.0049},{"period":"1month","weight":-0.0268},{"period":"3month","weight":0.0761},{"period":"6month","weight":-0.0047},{"period":"1year","weight":-0.0507},{"period":"ytd","weight":-0.0311}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"石四药集团有限公司,前称为利君国际医药（控股）有限公司，是一家主要从事研究、开发、制造及向医院及分销商销售药物产品的投资控股公司。公司的产品主要包括静脉输液的成药、原料药及医用材料。该公司的产品主要包括非聚氯乙烯软袋输液、聚丙烯塑瓶输液和玻璃瓶输液。该公司的产品还包括盐酸倍他司汀、盐酸氨溴索、盐酸罗哌卡因和多索茶碱以及原料药，包括咖啡因、茶碱、氨茶碱、甲硝唑和硝苯地平。","yearOnYearQuotes":[{"month":1,"riseRate":0.52381,"avgChangeRate":0.008129},{"month":2,"riseRate":0.52381,"avgChangeRate":0.020564},{"month":3,"riseRate":0.666667,"avgChangeRate":0.079144},{"month":4,"riseRate":0.47619,"avgChangeRate":0.030994},{"month":5,"riseRate":0.47619,"avgChangeRate":0.01054},{"month":6,"riseRate":0.47619,"avgChangeRate":0.060529},{"month":7,"riseRate":0.380952,"avgChangeRate":-0.020932},{"month":8,"riseRate":0.380952,"avgChangeRate":-0.010111},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.042167},{"month":10,"riseRate":0.45,"avgChangeRate":-0.001961},{"month":11,"riseRate":0.65,"avgChangeRate":0.086395},{"month":12,"riseRate":0.5,"avgChangeRate":-0.009036}],"exchange":"SEHK","name":"石四药集团","nameEN":"SSY GROUP"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"石四药集团(02005)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供石四药集团(02005)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"石四药集团,02005,石四药集团股票,石四药集团股票老虎,石四药集团股票老虎国际,石四药集团行情,石四药集团股票行情,石四药集团股价,石四药集团股市,石四药集团股票价格,石四药集团股票交易,石四药集团股票购买,石四药集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"石四药集团(02005)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供石四药集团(02005)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}